|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...90919293949596979899100...156157» |
- Enrollment change: Spine QCT: Spine Quantitative Computed Tomography (QCT) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=127, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
N=230 --> 127
- ||| Clinical: Observational Study of Meloxicam in Any Labeled Indication (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=13039, Completed, Sponsor: Boehringer Ingelheim
- ||| sovleplenib (HMPL-523) / Hutchmed
Enrollment open: A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 (clinicaltrials.gov) - Jul 8, 2014
P1, N=72, Recruiting, Sponsor: Hutchison Medipharma Limited
N=230 --> 127 Not yet recruiting --> Recruiting
- Trial completion: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jul 8, 2014
P2, N=30, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 6, 2014
P=N/A, N=1232, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - Jul 4, 2014
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Dec 2015
- |||| Epratucyn (epratuzumab) / Gilead
Trial primary completion date: EMBODY 1: Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 4, 2014
P3, N=780, Active, not recruiting, Sponsor: UCB, Inc.
Trial primary completion date: Feb 2015 --> Dec 2015 Trial primary completion date: Nov 2014 --> Apr 2015
- | Enrollment closed: Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (clinicaltrials.gov) - Jul 4, 2014
P2, N=30, Active, not recruiting, Sponsor: Jacobus Pharmaceutical
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- || Trial primary completion date: REACTIV: Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=75, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2014 --> Sep 2014
- | toreforant (JNJ-38518168) / J&J
Trial termination: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate (clinicaltrials.gov) - Jul 2, 2014
P2, N=272, Terminated, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Apr 2014 --> Sep 2014 Active, not recruiting --> Terminated; The decision was made to prematurely discontinue this trial due to lack of efficacy.
- mycophenolate mofetil / Generic mfg.
Trial initiation date: Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis (clinicaltrials.gov) - Jul 2, 2014
P4, N=150, Completed, Sponsor: Tuen Mun Hospital
Active, not recruiting --> Terminated; The decision was made to prematurely discontinue this trial due to lack of efficacy. Initiation date: Jun 2004 --> Sep 2005
- atacicept (VT-001) / Vera Therap
Enrollment change, Combination therapy: The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis (clinicaltrials.gov) - Jul 2, 2014
P2/3, N=6, Terminated, Sponsor: EMD Serono
Initiation date: Jun 2004 --> Sep 2005 N=200 --> 6
- mycophenolate mofetil / Generic mfg.
Enrollment change: Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis (clinicaltrials.gov) - Jul 2, 2014
P4, N=150, Completed, Sponsor: Tuen Mun Hospital
N=200 --> 6 N=100 --> 150
- ||| Clinical: Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=9984, Completed, Sponsor: Boehringer Ingelheim
- mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial initiation date: Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis (clinicaltrials.gov) - Jul 2, 2014
P4, N=150, Completed, Sponsor: Tuen Mun Hospital
N=100 --> 150 Active, not recruiting --> Completed | N=100 --> 150 | Initiation date: Jun 2004 --> Sep 2005
- Trial completion: Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=617, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed | N=100 --> 150 | Initiation date: Jun 2004 --> Sep 2005 Recruiting --> Completed
- Trial primary completion date: Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis (IMPACTAR) (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=10000, Enrolling by invitation, Sponsor: Iniciativa Mexicana de Pacientes con Osteoartritis y Artritis Reumatoide
Recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- Benlysta (belimumab) / GSK
Trial primary completion date, IO biomarker: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (clinicaltrials.gov) - Jul 1, 2014
P2, N=18, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Jun 2016 --> Sep 2014
- fletikumab (NNC109-0012) / Novo Nordisk
Trial initiation date, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jul 1, 2014
P2, N=42, Not yet recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jun 2016 --> Sep 2014 Initiation date: Mar 2014 --> Sep 2014
- ||| Betaseron (IFN-β-1b) / Bayer
Enrollment open, Adherence: BETAEVAL: BAY86-5046 (Betaseron), Non Interventional Studies (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=150, Recruiting, Sponsor: Bayer
Initiation date: Mar 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- | Benlysta (belimumab) / GSK
Enrollment closed, Trial primary completion date, IO biomarker: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (clinicaltrials.gov) - Jul 1, 2014
P2, N=18, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2014
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=67, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2014 Trial primary completion date: Mar 2014 --> Aug 2014
- Trial primary completion date: TeensConnect: Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes (clinicaltrials.gov) - Jul 1, 2014
P3, N=120, Active, not recruiting, Sponsor: Yale University
Trial primary completion date: Mar 2014 --> Aug 2014 Trial primary completion date: Dec 2013 --> May 2015
- leucovorin calcium / Generic mfg.
Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Jul 1, 2014
P2, N=144, Recruiting, Sponsor: University of Arkansas
Trial primary completion date: Dec 2013 --> May 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment change: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=67, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Sep 2014 --> Sep 2015 N=44 --> 67
- Clinical: SportGuard: Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: University of Ljubljana, Faculty of Medicine
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open, Enrollment change, Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=67, Recruiting, Sponsor: Novo Nordisk A/S
N=44 --> 67 Completed --> Recruiting | N=44 --> 67 | Trial primary completion date: Mar 2014 --> Aug 2014
- | Enrollment closed, Trial primary completion date: TeensConnect: Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes (clinicaltrials.gov) - Jul 1, 2014
P3, N=120, Active, not recruiting, Sponsor: Yale University
Completed --> Recruiting | N=44 --> 67 | Trial primary completion date: Mar 2014 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> May 2015
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=46, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> May 2015 Active, not recruiting --> Completed
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: A Long-Term Extension Study of WA22763 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 27, 2014
P3, N=11, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Sep 2015
- || Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P2, N=102, Active, not recruiting, Sponsor: Biogen Idec
Trial primary completion date: Dec 2014 --> Sep 2015 Trial primary completion date: Sep 2013 --> Nov 2014
- Trial primary completion date: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=16, Completed, Sponsor: University of Florida
Trial primary completion date: Sep 2013 --> Nov 2014 Trial primary completion date: Dec 2013 --> Jun 2012
- Enrollment change: Assessment of the Disease Severity and Treatment Patterns of Rheumatoid Arthritis in Eastern Europe, Middle East and North African Countries (P08167) (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2013 --> Jun 2012 N=10000 --> 0
- Enrollment change: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=16, Completed, Sponsor: University of Florida
N=10000 --> 0 N=20 --> 16
- | Tysabri (natalizumab) / Biogen, Royalty
Phase classification: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P2, N=102, Active, not recruiting, Sponsor: Biogen Idec
N=20 --> 16 Phase classification: P=N/A --> P2
- Clinical: Reproductive Health in Men and Women With Vasculitis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=467, Completed, Sponsor: University of South Florida
- | Ninlaro (ixazomib) / Takeda
New P1 trial: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) (clinicaltrials.gov) - Jun 27, 2014
P1, N=40, Not yet recruiting, Sponsor: Takeda
- | andecaliximab (GS-5745) / Gilead
New P1 trial, P1 data, PK/PD data: Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 27, 2014
P1, N=20, Not yet recruiting, Sponsor: Gilead Sciences
- Enrollment open: Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=50, Recruiting, Sponsor: NHS Greater Glasgow and Clyde
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting
- Biomarker, Enrollment open: Neuroretinal Biomarkers in Neurodegenerative Diseases (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=80, Recruiting, Sponsor: University of Edinburgh
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Phase classification, Trial primary completion date: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 27, 2014
P2, N=102, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | Trial primary completion date: Sep 2013 --> Nov 2014
- | Trial completion, Enrollment change, Trial primary completion date: Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=16, Completed, Sponsor: University of Florida
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | Trial primary completion date: Sep 2013 --> Nov 2014 Active, not recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Dec 2013 --> Jun 2012
- Trial completion: Genetics of Rheumatoid Arthritis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=39, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Active, not recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Dec 2013 --> Jun 2012 Active, not recruiting --> Completed
- Trial primary completion date: DiabCare Asia: A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1832, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Trial primary completion date: Feb 2010 --> Feb 2009
- Trial completion: Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS (clinicaltrials.gov) - Jun 27, 2014
P1, N=24, Completed, Sponsor: The Cleveland Clinic
Trial primary completion date: Feb 2010 --> Feb 2009 Active, not recruiting --> Completed
- || Orencia (abatacept) / BMS
Trial primary completion date: Safety Study of Abatacept to Treat Rheumatoid Arthritis (A) (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=40000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Mar 2017
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: RELIEF: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 26, 2014
P4, N=218, Recruiting, Sponsor: Merck KGaA
Trial primary completion date: Dec 2015 --> Mar 2017 Not yet recruiting --> Recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=400, Not yet recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Jun 2016
- Biomarker, Trial primary completion date: An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=80, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: May 2015 --> Aug 2015
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=44, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2015 --> Aug 2015 Trial primary completion date: Dec 2014 --> Jun 2014